Literature DB >> 21557214

Dichloroacetate inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cells.

Serena Vella1, Matteo Conti, Roberta Tasso, Ranieri Cancedda, Aldo Pagano.   

Abstract

The small, water soluble molecule Dichloroacetate (DCA) is recently arousing lively interests in the field of cancer therapy for it has been shown to be able to inhibit the growth of human tumors acting specifically on the mitochondria of cancer cells without perturbing the physiology of nonmalignant cells. Neuroblastoma was one of the tumor types on which DCA was considered ineffective as it is composed of cells with few recognized mitochondrial anomalies. Neuroblastoma, however, is composed of different cell types in terms of metabolism, phenotype and malignant potential. Despite the above prediction, in this work, we show that (i) DCA exhibits an unexpected anticancer effect on NB tumor cells and (ii) this effect is selectively directed to very malignant NB cells, whereas the more differentiated/less malignant NB cells are refractory to DCA treatment. This result supports the need of a detailed investigation of DCA anticancer properties against this tumor type with the final aim of its possible use as therapeutic agent.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21557214     DOI: 10.1002/ijc.26173

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

Review 1.  Metabolic modulation of cancer: a new frontier with great translational potential.

Authors:  Adam Kinnaird; Evangelos D Michelakis
Journal:  J Mol Med (Berl)       Date:  2015-01-14       Impact factor: 4.599

2.  DCA promotes progression of neuroblastoma tumors in nude mice.

Authors:  Benedikt Feuerecker; Christof Seidl; Sabine Pirsig; Gernot Bruchelt; Reingard Senekowitsch-Schmidtke
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

3.  Silencing gastrin-releasing peptide receptor suppresses key regulators of aerobic glycolysis in neuroblastoma cells.

Authors:  Eric J Rellinger; Carmelle Romain; SunPhil Choi; Jingbo Qiao; Dai H Chung
Journal:  Pediatr Blood Cancer       Date:  2015-01-28       Impact factor: 3.167

4.  Targeting glucose metabolism in cancer: new class of agents for loco-regional and systemic therapy of liver cancer and beyond?

Authors:  Lynn Jeanette Savic; Julius Chapiro; Gregor Duwe; Jean-François Geschwind
Journal:  Hepat Oncol       Date:  2016-01-01

5.  Comparison of spheroids formed by rat glioma stem cells and neural stem cells reveals differences in glucose metabolism and promising therapeutic applications.

Authors:  Marie Morfouace; Lisenn Lalier; Muriel Bahut; Virginie Bonnamain; Philippe Naveilhan; Catherine Guette; Lisa Oliver; Naig Gueguen; Pascal Reynier; Francois M Vallette
Journal:  J Biol Chem       Date:  2012-07-10       Impact factor: 5.157

Review 6.  Restoration of mitochondria function as a target for cancer therapy.

Authors:  Tariq A Bhat; Sandeep Kumar; Ajay K Chaudhary; Neelu Yadav; Dhyan Chandra
Journal:  Drug Discov Today       Date:  2015-03-09       Impact factor: 7.851

Review 7.  Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication.

Authors:  Minjong Lee; Jung-Hwan Yoon
Journal:  World J Biol Chem       Date:  2015-08-26

Review 8.  Targeting malignant mitochondria with therapeutic peptides.

Authors:  Jonathan E Constance; Carol S Lim
Journal:  Ther Deliv       Date:  2012-08

Review 9.  Energy metabolism in neuroblastoma and Wilms tumor.

Authors:  Sepideh Aminzadeh; Silvia Vidali; Wolfgang Sperl; Barbara Kofler; René G Feichtinger
Journal:  Transl Pediatr       Date:  2015-01

10.  Dichloroacetate, an inhibitor of pyruvate dehydrogenase kinases, inhibits platelet aggregation and arterial thrombosis.

Authors:  Manasa K Nayak; Nirav Dhanesha; Prakash Doddapattar; Omar Rodriguez; Vijay K Sonkar; Sanjana Dayal; Anil K Chauhan
Journal:  Blood Adv       Date:  2018-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.